Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.44 |
| ▸ | ELANE | P08246 | 7/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30766024 | 0.92 | PDE4B (0.44) | CASP1PDE4BHDAC1HDAC8HDAC6 | |
| SCHEMBL30766058 | 0.86 | ELANE (0.43) | CASP1HDAC1HDAC8HDAC6ELANE | |
| SCHEMBL30765889 | 0.83 | ELANE (0.38) | CASP1PDE4BELANE | |
| SCHEMBL30765590 | 0.78 | ELANE (0.45) | CASP1HDAC1HDAC8HDAC6ELANE | |
| SCHEMBL30765557 | 0.76 | CASP1 (0.46) | CASP1ELANE | |
| SCHEMBL6240894 | 0.75 | ELANE (0.51) | CASP1HDAC1ELANE | |
| SCHEMBL6803430 | 0.75 | ALDH1A1 (0.52) | CASP1ELANE | |
| SCHEMBL30766084 | 0.74 | CASP1 (0.49) | CASP1ELANE | |
| SCHEMBL30765862 | 0.74 | HDAC1 (0.50) | CASP1HDAC1HDAC8HDAC6ELANE | |
| SCHEMBL6240974 | 0.73 | RAB9A (0.55) | CASP1ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |